<?xml version='1.0' encoding='utf-8'?>
<document id="27342643"><sentence text="Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats." /><sentence text="Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed" /><sentence text="" /><sentence text="The aim of this study is to characterize the preclinical profile of ITI-214, a potent inhibitor of phosphodiesterase 1 (PDE1)" /><sentence text="" /><sentence text="ITI-214 was assayed for inhibition of PDE1 versus other PDE enzyme families using recombinant human PDE enzymes and for off-target binding to 70 substrates (General SEP II diversity panel; Caliper Life Sciences)" /><sentence text=" Effects of ITI-214 (0" /><sentence text="1-10 mg/kg, po) on memory performance were assayed in rats using the novel object recognition (NOR) paradigm, with drug given at specified time points prior to or following exposure to objects in an open field" /><sentence text=" ITI-214 was evaluated for potential drug-drug interaction with risperidone in rats using conditioned avoidance response (CAR) and pharmacokinetic assessments"><entity charOffset="64-75" id="DDI-PubMed.27342643.s9.e0" text="risperidone" /></sentence><sentence text="" /><sentence text="ITI-214 inhibited PDE1A (K i = 33 pmol) with &gt;1000-fold selectivity for the nearest other PDE family (PDE4D) and displayed minimal off-target binding interactions in a 70-substrate selectivity profile" /><sentence text=" By using specific timing of oral ITI-214 administration, it was demonstrated in the NOR that ITI-214 is able to enhance acquisition, consolidation, and retrieval memory processes" /><sentence text=" All memory effects were in the absence of effects on exploratory behavior" /><sentence text=" ITI-214 did not disrupt the risperidone pharmacokinetic profile or effects in CAR"><entity charOffset="29-40" id="DDI-PubMed.27342643.s14.e0" text="risperidone" /></sentence><sentence text="" /><sentence text="ITI-214 improved the memory processes of acquisition, consolidation, and retrieval across a broad dose range (0" /><sentence text="1-10 mg/kg, po) without disrupting the antipsychotic-like activity of a clinical antipsychotic medication, specifically risperidone"><entity charOffset="120-131" id="DDI-PubMed.27342643.s17.e0" text="risperidone" /></sentence><sentence text=" Clinical development of ITI-214 is currently in progress" /><sentence text="" /></document>